DelveInsight Business Research LLP

DelveInsight’s “Monkeypox- Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Monkeypox market report provides current treatment practices, emerging drugs, Monkeypox market share of the individual therapies, and current and forecasted Monkeypox market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Monkeypox treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Some of the Key Facts of the Monkeypox Market Report:

• Monkeypox is usually a self-limited disease with symptoms lasting from 2 to 4 weeks. Severe cases can occur. In recent times, the case fatality ratio has been around 3–6%.

Key Benefits of the Monkeypox Market Report

• The report covers the descriptive overview of Monkeypox, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Monkeypox epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Monkeypox are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of Monkeypox market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Monkeypox market

Got queries? Click here to know more about the Monkeypox Market Landscape

Monkeypox Overview

Monkeypox is a viral zoonosis (a virus transmitted to humans from animals) with symptoms similar to those seen in the past in smallpox patients, although it is clinically less severe. Monkeypox virus is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family. There are two distinct genetic clades of the monkeypox virus: the central African (Congo Basin) clade and the west African clade. The Congo Basin clade has historically caused more severe diseases and was thought to be more transmissible. The geographical division between the two clades has so far been in Cameroon, the only country where both virus clades have been found.

Monkeypox Epidemiological Insights:

• In 1970, monkeypox was first associated with an illness a disease in humans in the Democratic Republic of the Congo (formerly Zaire), in the town of Basankusu, Équateur Province. Although it was once thought to be uncommon in humans, cases increased since the 1980s, possibly as a result of waning immunity since the stopping of routine smallpox vaccination.

• Between 1981 and 1986 WHO surveillance in DRC/Zaire recorded 338 confirmed cases and 33 deaths (CFR 9.8%).[71] In 1996–1997, the second outbreak of human illness was identified in DRC/Zaire and between 1991 and 1999, 511 cases were reported in DRC/Zaire. Clade I of the disease remains endemic in DRC and has a higher CFR than the other genetic clade in Western Africa.

• By May 2022, the case fatality rate (CFR) of past outbreaks was around 3%–6%, while the CFR of the 2022 outbreak remains below 1%. No human-to-human transmission was documented until the 2022 monkeypox outbreak in Europe. Clade II had an outbreak – the first outbreak of monkeypox outside of Africa – in the Midwestern United States among owners of pet prairie dogs in 2003. Seventy-one people were reportedly infected, of whom none died

Monkeypox Epidemiological Segmentation 

• Monkeypox prevelant cases 

• Monkeypox age-specific cases 

• Monkeypox  gender-specific cases 

• Monkeypox cases based on race 

Monkeypox Market Outlook 

The Monkeypox market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Monkeypox market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

 This segment gives a thorough detail of the Monkeypox market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Monkeypox market in 7MM is expected to change in the study period 2019-2032.

Learn more by requesting for sample @ Monkeypox Market Landscape

Table of Contents

1.  Key Insights 

2.  Report Introduction 

3.  Executive Summary of Monkeypox  Market 

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  The United States 

7.  EU 5

8.  Monkeypox  Market  Emerging Therapies

9.  Monkeypox  Market Market Outlook

10.  Market Drivers 

11.  Market Barriers 

12.  Market Access and Reimbursement of Therapies

13.  Appendix

14.  Monkeypox  Market  Report Methodology

15.  DelveInsight Capabilities

16.  Disclaimer

17.  About DelveInsight

Click here to read more about Monkeypox Market Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com